Spots Global Cancer Trial Database for recurrent hematologic malignancy

Every month we try and update this database with for recurrent hematologic malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	NCT03272633	Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat...	Allogeneic Hema... Irradiated Allo...	18 Years -	Rutgers, The State University of New Jersey
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	NCT01822509	Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	NCT02805075	Hematopoietic a... Recurrent Hemat...	Fructooligosacc... Laboratory Biom...	18 Years -	Stanford University
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	NCT03272633	Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat...	Allogeneic Hema... Irradiated Allo...	18 Years -	Rutgers, The State University of New Jersey
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	NCT02805075	Hematopoietic a... Recurrent Hemat...	Fructooligosacc... Laboratory Biom...	18 Years -	Stanford University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: